# A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

> **NCT00149981** · — · NO_LONGER_AVAILABLE · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Organ Transplantation

## Interventions

- **DRUG:** everolimus (RAD)

## Key facts

- **NCT ID:** NCT00149981
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2019-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00149981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00149981, "A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00149981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*